Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 68083-249

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 68083-249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxorubicin-spl-100-ml-carton (Doxorubicin Spl 100 mL Carton)

This product is a 100 mL mult-dose vial of DOXOrubicin Hydrochloride Injection, USP. It contains 200 mg/100 mi (2 mg/mL) of the medication. The usual dosage should be found in the package insert. The medication should be stored under refrigeration between 2°C to 8°C (36°F to 46°F). The product warning indicates that it may cause severe tissue damage or vesicant. It is for intravenous use only. The manufacturer is Gland Pharma Limited located in India. There is additional information that is not clearly recognized by the software.*

FDA Label Image

Doxorubicin-spl-100-ml-vial (Doxorubicin Spl 100 mL Vial)

FDA Label Image

Doxorubicin-spl-25-ml-vial (Doxorubicin Spl 25 mL Vial)

FDA Label Image

Doxorubicin-spl-5-ml-carton (Doxorubicin Spl 5 mL Carton)

FDA Label Image

Doxorubicin-spl-struc (Doxorubicin Spl Struc)

FDA Label Image

Doxorubicin-spl-25-ml-carton (Doxorubicin Spl 25 mL Carton)

This is a prescription medication called DOXOrubicin Hydrochloride Injection, USP. The medication is a sterile, isotonic solution containing 2mg of DOXOrubicin Hydrochloride per milliliter. It is used for intravenous use only. This medication is packaged in a 25mL single-dose vial that should be stored under refrigeration and protected from light until used. Users should discard unused portions. Severe celulitis, vesication, and fissue necrosis can occur in case DOXOrubicin is extravasated.*

FDA Label Image

Doxorubicin-spl-5-ml-vial (Doxorubicin Spl 5 mL Vial)

DOXOrubicin Hydrochloride Injection, USP is a cytotoxic agent used for intravenous use only. It is available in a 10 mg/5 mL single-dose vial. Any unused portion should be discarded. The text contains some gibberish characters and cannot provide any other useful information.*

FDA Label Image

Doxorubicin-spl-graph1 (Doxorubicin Spl Graph1)

The text is referring to hazard ratio and comparison of different treatment trials (NSABP B-15, SECSG 2, ONCOFRANCE, SE Sweden BCG A, NSABG Israel Br0283, Austrian BCSG 3) using Doxo based (6 studies) in terms of effectiveness in comparison to CMF. The text mentions that Doxo based treatment is better than CMF treatment in some cases and worse in others. Additionally, it provides the boundary of non-inferiority with CMF as 106 with the retention of 75% of CMF effect.*

FDA Label Image

Doxorubicin-spl-graph2 (Doxorubicin Spl Graph2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.